| Bioactivity | PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2]. | ||||||||||||
| Target | A2A adenosine | ||||||||||||
| In Vivo | PD 117519 (2-10 mg/kg; oral administration; 16-24 hours; male beagle dogs) treatment produces significant hemodynamic changes at Tmax (4 hours) follows by acute coronary vascular injury that is evident at 16 hours postdosing.Treatment with 2 or 10 mg/kg of PD 117519 produces significant increases in mean heart rate and decreases in mean indirectsystolic blood pressure at time of highest drug exposure, 4 hours postdosing[3]. Animal Model: | ||||||||||||
| Name | PD 117519 | ||||||||||||
| CAS | 96392-15-3 | ||||||||||||
| Formula | C19H21N5O4 | ||||||||||||
| Molar Mass | 383.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Reynolds DL, et al. Liquid chromatographic analysis of the adenosine agonist PD 117519 in dog plasma. J Pharm Biomed Anal. 1991;9(4):345-9. [2]. Tobin GA, et al. The role of eNOS phosphorylation in causing drug-induced vascular injury. Toxicol Pathol. 2014 Jun;42(4):709-24. [3]. Enerson BE, et al. Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression. Toxicol Pathol. 2006;34(1):27-32. |